Psychedelic Lobbying and Regulatory Capture
Not all lobbying campaigns are problematic — the goal should be for regulators to leverage industry insights while maintaining independence in decision-making.

Not all lobbying campaigns are problematic — the goal should be for regulators to leverage industry insights while maintaining independence in decision-making.

There is little consensus in defining “psychedelic.” Yet, research on and access to these substances hinges on what gets included under this umbrella.

Petrie-Flom Center intern James René Jolin and Executive Director Susannah Baruch discuss the FDA’s approval of over-the-counter birth control.

The FDA has recently turned its attention to the growing use of artificial intelligence and machine learning in drug development.

What are the risks of using generative AI systems like ChatGPT in medical practice, and who is ultimately held responsible for patient harm?

While issues of influence affecting Supreme Court Justices attract the most attention, the factors that make Justices targets extend across the entire federal judiciary.

The regulatory landscape of health-related products contains loopholes that allow false or misleading claims to proliferate.
